Application of Remimazolam and Sufentanil in patients of non early extubation after neurosurgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046297

Enrollment

Unknown

Registered

2021-05-12

Start date

2021-05-05

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical illness

Interventions

Experimental group1:Remimazolam

Experimental group2:Dexmedetomidine

Experimental group:propofol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients transferred to ICU after neurosurgery; 2. Patients required mechanical ventilation for more than 24 hours wihch joint evaluation by neurosurgeons and critical care physicians; 3. Patients requiring analgesia and sedation during mechanical ventilation; 4. Aged more than 18 years; 5. Patients with Glasgow score < 12; 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Myasthenia gravis; 3. Mental illness.

Design outcomes

Primary

Measure	Time frame
hospital stay in Intensive Care Unit ;Sedative dosage;Heart rate variability;Blood pressure variability;Incidence of arrhythmia;	—

Secondary

Measure	Time frame
Duration of mechanical ventilation;Time taken to titrate to ideal sedation target;Total price of sedatives;Incidence of delirium;Incidence of reintubation in 48 hours;	—

Countries

China

Contacts

Public ContactLu Tao

The First People's Hospital of Longquanyi District, Chengdu

715070730@qq.com+86 13882074452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026